Results 161 to 170 of about 20,052 (248)

Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This study aims to examine weight‐loss history and pre‐treatment concerns, and their associations with current functioning and well‐being in adults undergoing incretin‐based pharmacotherapy for obesity. Materials and Methods This cross‐sectional study analysed 411 adults treated with three different incretin‐based medications. Demographics,
Ali Kapan, Tobias Brandl, Thomas Waldhör, Othmar Moser, Richard Felsinger   +4 more
wiley   +1 more source

Complementary neuroprotective effects of semaglutide and papaya in diabetic encephalopathy via antioxidant and insulin-signaling pathways. [PDF]

Sci Rep
Zeweil MM, Ali MM, Shamaa MM, Mohammed FI, Kamal M, Zaki MSA, Alharthi A, Ahmed AA, Elkelish A, Abdel-Maksoud MS, Dossouvi KM, Khafaga AF.   +11 more
europepmc   +1 more source

Kardiológiai vonatkozású diabetológiai újdonságok = Novelties from diabetology with cardiological concerns [PDF]

, 2018
Jermendy, György
core   +1 more source

GLP‐1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The escalating use of Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is reshaping pharmaceutical consumption patterns and posing unprecedented challenges to healthcare systems worldwide. This study analyzes the landscape of GLP‐1 RA consumption, safety monitoring and regulatory oversight in Brazil.
Renato Lopes Hurtado, Angélica Amorim Amato, Hugo de Luca Corrêa, Dâmaris Silveira   +3 more
wiley   +1 more source

A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists. [PDF]

J Clin Med
Virk A, Allison K.
europepmc   +1 more source

Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims/Hypothesis Initial dose‐escalation has been shown to mitigate gastrointestinal adverse events in people treated with incretin‐based medications. We aimed to analyse dose‐response relationships for the proportion of study participants reporting nausea and vomiting among those exposed to incretin mimetics approved for Type 2 diabetes (GLP‐1
Michael A. Nauck, Viktoria Punov, Yu Mi Kang, Soo Lim   +3 more
wiley   +1 more source

Clinical Pharmacokinetics of Semaglutide: A Systematic Review

Drug Design, Development and Therapy
Xi-Ding Yang,1,2 Yong-Yu Yang1,3 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China; 2Phase I Clinical Trial Center, The Second Xiangya Hospital of Central South University ...
Yang XD, Yang YY
doaj  

Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. [PDF]

Eur Heart J
Park B, Dennis F, He AZ, Krishnaraj A, Bakbak E, Dennis CJ, Pan Y, Misner E, Thayanithy V, Lambotharan B, Lambotharan V, Lambotharan A, Mazer CD, Quan A, Teoh H, Hess DA, Verma S.   +16 more
europepmc   +1 more source

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction‐Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity‐management modalities exert weight‐independent hepatic effects remains uncertain.
Matteo Monami, Amanda Belluzzi, Silvio Buscemi, Luca Busetto, Ricardo Cohen, Maurizio De Luca, Andrea Galli, Edoardo Mannucci, Tarissa Z. Petry, Benedetta Ragghianti, Paolo Sbraccia, Dror Dicker   +11 more
wiley   +1 more source

Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights. [PDF]

Int J Gen Med
Li L, Jin L, Wang J.
europepmc   +1 more source